Primary biliary cholangitis (PBC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Primary biliary cholangitis (PBC)

Primary biliary cholangitis (PBC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver – called the intrahepatic bile ducts. The exact cause of primary biliary cholangitis is unknown. Literature suggest an overactive immune system, which may be genetic NIH external link, and unknown environmental triggers play a role in causing primary biliary cholangitis.

Possible environmental triggers include: infections, cigarette smoking, exposure to certain chemicals. Approximately 95 percent of people with PBC produce antibodies (known as “autoantibodies”) that act upon certain of the body’s own mitochondria (mitochondrial autoantigens, e.g., E2 component of pyruvate dehydrogenase complex [PDC-E2], E2 component of branched chain 2-oxo-acid dehydrogenase complex [BCOADC-E2]).

According to Thelansis about 65 out of every 100,000 women have PBC in the United States. Competitive landscape of Primary biliary cholangitis (PBC) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Primary biliary cholangitis (PBC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

KOLs insights of Primary biliary cholangitis (PBC) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: Primary biliary cholangitis (PBC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        EDP-305        Enanta Pharmaceuticals        Phase 2

2        Seladelpar        CymaBay Therapeutics, Inc.        Phase 3

3        Elafibranor        Genfit        Phase 3

4        LJN452        Novartis Pharmaceuticals        Phase 2

5        NGM282        NGM Biopharmaceuticals, Inc        Phase 2

6        Saroglitazar magnesium        Zydus Discovery DMCC        Phase 2

7        GKT137831        Genkyotex SA        Phase 2

8        Emtricitabine (FTC        Merck Sharp & Dohme Corp.        Phase 2

9        Obeticholic Acid (OCA)        Intercept Pharmaceuticals        Phase 3

10        rituximab        Genentech, Inc.        Phase 2

11        ustekinumab        Janssen Research & Development, LLC        Phase 2

12        HTD1801 (BUDCA)        HighTide Biopharma Pty Ltd        Phase 2

13        FFP104        Fast Forward Pharmaceuticals        Phase 2

14        LUM001        Mirum Pharmaceuticals, Inc.        Phase 2

15        TQA3526        Chia Tai Tianqing Pharmaceutical Group Co., Ltd.        Phase 2

16        OP-724        Ohara Pharmaceutical Co., Ltd.        Phase 1

17        CR845 1.0 mg        Cara Therapeutics, Inc.        Phase 2

18        Linerixibat        GlaxoSmithKline        Phase 3

19        Fenofibrate IDD-P        Shionogi Inc.        Phase 2

20        A4250        Albireo        Phase 1"